Overdose/Missed Dose

Cialis for erectile dysfunction (ED)

Hepatic Impairment: In patients with mild or moderate hepatic impairment, the dose of tadalafil should not exceed 10 mg. Because of insufficient information in patients with severe hepatic impairment, use of tadalafil in this group is not recommended. Tadalafil for once daily use has not been extensively evaluated in patients with mild or moderate hepatic impairment. Therefore, caution is advised if tadalafil for once daily use is prescribed to these patients. Because of insufficient information in patients with severe hepatic impairment, use of tadalafil in this group is not recommended.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	60mg	270 + 10 Pills	443.96€ 422.82€
Cialis Generic	5mg	20 Pills	41.99€ 39.99€
Cialis Soft Tabs	20mg	180 + 8 Pills	353.17€ 336.35€
Cialis Professional	20mg	60 + 2 Pills	183.83€ 175.08€
Cialis Generic	2.5mg	10 Pills	28.51€ 27.15€
Cialis Generic	10mg	20 Pills	48.23€ 45.93€
Cialis Original	20mg	22 + 2 Pills	129.20€ 123.05€
Cialis Black	80mg	10 Pills	43.27€ 41.21€
Cialis Generic	20mg	360 + 10 Pills	427.34€ 406.99€
Cialis Black	80mg	60 + 4 Pills	150.98€ 143.79€

Alcohol: Physicians should inform patients that substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Concomitant Use of Potent Inhibitors of Cytochrome P450 3A4 (CYP3A4): For patients taking potent inhibitors of CYP3A4 such as ritonavir, ketoconazole, and itraconazole, the dose of tadalafil tablets should be limited to 10 mg no more than once every 72 hours. If once daily use is prescribed the maximum recommended dose is 2.5 mg. Combination With Other PDE5 Inhibitors or Erectile Dysfunction Therapies: The safety and efficacy of combinations of tadalafil and other PDE5 inhibitors or treatments for erectile dysfunction have not been studied. Inform patients not to take tadalafil with cialis pricing 20mg other PDE5 inhibitors, including ADCIRCA®. Effects on Bleeding: Tadalafil has not been administered to patients with bleeding disorders or significant active peptic ulceration.

What About Other ED Medications?

Creatinine clearance 30 to 50 mL/min: For tadalafil tablets for daily use treatment of BPH or ED/BPH, start dosing at 2.5 mg and increase to 5 mg based upon individual response. Tadalafil tablets for use as needed, start dosing at 5 mg not more than once per day with a maximum dose of 10 mg not more than once every 48 hours. Hepatic Impairment: In patients with mild or moderate hepatic impairment, the dose of tadalafil should not exceed 10 mg. Because of insufficient information in patients with severe hepatic impairment, use of tadalafil in this group is not recommended. Tadalafil for once daily use has not been extensively evaluated in patients with mild or moderate hepatic impairment.

1. They Look Different

Therefore, caution is advised if tadalafil for once daily use is prescribed to these patients. Because of insufficient information in patients with severe hepatic impairment, use of tadalafil in this group is not recommended. Alcohol: Physicians should inform patients that substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Concomitant Use of Potent Inhibitors of Cytochrome P450 3A4 (CYP3A4): For patients taking potent inhibitors of CYP3A4 such as ritonavir, ketoconazole, and itraconazole, the dose of tadalafil tablets should be limited to 10 mg no more than once every 72 hours. If once daily use is prescribed the maximum recommended dose is 2.5 mg. Although tadalafil has not been shown to increase bleeding times in healthy subjects, use in patients with bleeding disorders or significant active peptic ulceration should be based upon a careful risk-benefit assessment and caution.

Tadalafil (generic Cialis®)

government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets; compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks; other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at and Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. 1 Cialis® is a registered trademark of Eli Lilly and Company.

Can tadalafil treat conditions other than erectile dysfunction?

Teva Pharmaceutical Industries Ltd.IR ContactsUnited StatesKevin C. Mannix, 215-591-8912orIsraelRan Meir, 215-591-3033orPR ContactsUnited StatesElizabeth DeLuca, 267-468-4329orIsraelYonatan Beker, 972 (54) 888 5898 Get 25% off on 1st online pharmacy purchase. It increases blood flow to specific areas of the body, including the penis, which helps achieve and maintain an erection when sexually stimulated. In men with BPH, it helps relax the muscles of the bladder and prostate, thereby improving urinary symptoms. Counseling Patients About Sexually Transmitted Diseases: The use of tadalafil offers no protection against sexually transmitted diseases.

The patent for Cialis expired in 2018, allowing generics on the market.
Many online pharmacies sell generic Cialis, but check for reputable sources.
Generic Cialis is often available in the same dosages as the brand.
Insurance plans may cover generic Cialis to reduce out-of-pocket costs.

Standard	Description	Certifying Agency	Typical Testing Methods
GMP (Good Manufacturing Practice)	Ensures consistent quality	WHO, FDA	Assay, dissolution tests
USP Standards	Pharmacopoeia compliance	U.S. Pharmacopeia	Identity, purity tests
Bioequivalence Testing	Similar absorption to brand	FDA, EMA	Pharmacokinetic studies

Common Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 2%) were headache, flushing, dyspepsia, nasal congestion, back pain, myalgia, pain in limb, naspharyngitis, upper respiratory tract infection, cough, diarrhea, urinary tract infection, gastroesophageal reflux disease, abdominal pain, gastroenteritis, and hypertension.

Patent laws protect branded Cialis until they expire, enabling generics afterward.
The efficacy and safety of generic Cialis are supported by extensive research.
Patients with prescriptions can often opt for generic Cialis for savings.
Regulations ensure that generic Cialis must be therapeutically equivalent to original.

For more information, please see accompanying Full Prescribing Information. A copy may be requested from Teva US Medical Information at 888-4-TEVA-USA (888-838-2872) or druginfo@tevapharm.com, or Teva’s Public Relations or Investor Relations contacts. Teva Pharmaceutical Industries Ltd.

More about Cialis (tadalafil)

A copy may be requested from Teva US Medical Information at 888-4-TEVA-USA (888-838-2872) or druginfo@tevapharm.com, or Teva’s Public Relations or Investor Relations contacts. Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale.

Alternatives for ED and BPH

We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. This press release contains forward-looking statements within the meaning of the Private white cialis pill Securities Litigation Reform Act of 1995 regarding Teva's tadalafil tablets, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: The uncertainty of the commercial success of our generic version of tadalafil, including due to a potential launch of an Authorized Generic version; our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; competition from companies with greater resources and capabilities; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our products, both from competing products and increased regulation; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; our ability to take advantage of high-value opportunities; the difficulty and expense of obtaining licenses to proprietary technologies; and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; our business and operations in general, including: failure to effectively execute the restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the ongoing review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale.

FDA approval confirms that generic Cialis is bioequivalent to the brand.
The availability of generic Cialis increases the accessibility of ED treatment.
Patients report similar satisfaction levels using generic and brand-name Cialis.
Price differences make generic Cialis a popular choice among patients.

What do Penile Problems Look Like?

Are they approved by the FDA (Food and Drug Administration)?

This press release contains forward-looking statements within the meaning of the Private white cialis pill Securities Litigation Reform Act of 1995 regarding Teva's tadalafil tablets, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.

Comparing Which Works Faster

What are the serious side effects of tadalafil?

Important factors that could cause or contribute to such differences include risks relating to: The uncertainty of the commercial success of our generic version of tadalafil, including due to a potential launch of an Authorized Generic version; our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; competition from companies with greater resources and capabilities; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our products, both from competing products and increased regulation; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; our ability to take advantage of high-value opportunities; the difficulty and expense of obtaining licenses to proprietary technologies; and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; our business and operations in general, including: failure to effectively execute the restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the ongoing review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets; compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks; other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at and Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise.

The cost difference between Cialis and generic Cialis can be significant.
Generic Cialis provides a legal and safe alternative to the brand.
The active ingredient in all Cialis variants remains tadalafil.
Consult a doctor to confirm if generic Cialis is suitable for your needs.

You are cautioned not to put undue reliance on these forward-looking statements. 1 Cialis® is a registered trademark of Eli Lilly and Company.

Aspect	Brand Cialis	Generic Cialis
Price	Higher	Lower
Name Recognition	Yes	No
Manufacturing Brand	Eli Lilly	Multiple Brands
Prescriptions Required	Yes	Yes

How much is generic Cialis?

Combination With Other PDE5 Inhibitors or Erectile Dysfunction Therapies: The safety and efficacy of combinations of tadalafil and other PDE5 inhibitors or treatments for erectile dysfunction have not been studied. Inform patients not to take tadalafil with cialis pricing 20mg other PDE5 inhibitors, including ADCIRCA®. Effects on Bleeding: Tadalafil has not been administered to patients with bleeding disorders or significant active peptic ulceration. Although tadalafil has not been shown to increase bleeding times in healthy subjects, use in patients with bleeding disorders or significant active peptic ulceration should be based upon a careful risk-benefit assessment and caution. Counseling Patients About Sexually Transmitted Diseases: The use of tadalafil offers no protection against sexually transmitted diseases.

How long does tadalafil remain effective?

Counseling patients about the protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV) should be considered. Consideration of Other Urological Conditions Prior to Initiating Treatment for BPH: Prior to initiating treatment with tadalafil for BPH, consideration should be given to other urological conditions that may cause similar symptoms. In addition, prostate cancer and BPH may coexist. Common Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 2%) were headache, flushing, dyspepsia, nasal congestion, back pain, myalgia, pain in limb, naspharyngitis, upper respiratory tract infection, cough, diarrhea, urinary tract infection, gastroesophageal reflux disease, abdominal pain, gastroenteritis, and hypertension. For more information, please see accompanying Full Prescribing Information. It increases blood flow to specific areas of the body, including the penis, which helps achieve and maintain an erection when sexually stimulated. In men with BPH, it helps relax the muscles of the bladder and prostate, thereby improving urinary symptoms.

Identifying Authentic Generic Cialis from Counterfeits